EA 3571
Alternative Names: EA-3571Latest Information Update: 28 Jun 2025
At a glance
- Originator EA Pharma
- Class Hepatoprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Non-alcoholic steatohepatitis
Most Recent Events
- 28 Jun 2025 No recent reports of development identified for phase-I development in Non-alcoholic-steatohepatitis(In volunteers) in Japan (PO)
- 15 Nov 2024 Pharmacodynamics data from preclinical studies in Non-alcoholic steatohepatitis at 75th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2024)
- 15 Nov 2024 Pharmacokinetics, pharmacodynamics and adverse events data from a phase I trial in Non-alcoholic steatohepatitis presented at Liver Meeting 2024: 75th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2024)